Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
greatest decrease » treatment decreased (Expand Search), greater increase (Expand Search)
greater disease » greater decrease (Expand Search), related disease (Expand Search), greater sense (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
greatest decrease » treatment decreased (Expand Search), greater increase (Expand Search)
greater disease » greater decrease (Expand Search), related disease (Expand Search), greater sense (Expand Search)
-
2221
The characteristics of patient groups were used to prove the method’s applicability.
Published 2025Subjects: -
2222
-
2223
-
2224
-
2225
ROS, K<sup>+</sup> efflux and cathepsin B are required for NLRP3 activation.
Published 2025Subjects: -
2226
-
2227
-
2228
-
2229
Differences in health-related quality of life indexes after disease onset between groups.
Published 2025Subjects: -
2230
Changes in subcutaneous fat thickness and muscle mass (Approximately here).
Published 2025Subjects: -
2231
-
2232
-
2233
Ba/F3 EML4-ALK<sup>mutants</sup> exhibit variable dose-response to ABT-199 treatment.
Published 2025Subjects: -
2234
-
2235
-
2236
-
2237
-
2238
-
2239
-
2240